On September 7, 2024, Vivos Therapeutics, Inc., a Delaware-incorporated company listed on the Nasdaq Stock Market under the symbol VVOS, announced the Board of Directors' approval of the 2024 Omnibus Equity Incentive Plan, pending stockholder approval. This plan is set to replace the existing 2019 Stock Option and Stock Issuance Plan. The new incentive plan aims to align the interests of non-employee directors, officers, employees, and consultants with those of the company's stockholders by providing various stock-related awards. The plan will be presented for stockholder approval at the 2024 Annual Meeting. If approved, 1,600,000 shares of common stock will be available for future awards, and no further awards will be granted under the 2019 Plan. Additionally, contingent stock option awards were approved for...Show More

On September 7, 2024, Vivos Therapeutics, Inc., a Delaware-incorporated company listed on the Nasdaq Stock Market under the symbol VVOS, announced the Board of Directors' approval of the 2024 Omnibus Equity Incentive Plan, pending stockholder approval. This plan is set to replace the existing 2019 Stock Option and Stock Issuance Plan. The new incentive plan aims to align the interests of non-employee directors, officers, employees, and consultants with those of the company's stockholders by providing various stock-related awards. The plan will be presented for stockholder approval at the 2024 Annual Meeting. If approved, 1,600,000 shares of common stock will be available for future awards, and no further awards will be granted under the 2019 Plan. Additionally, contingent stock option awards were approved for executive officers and other personnel, which will be void if stockholder approval is not obtained. Furthermore, the company has approved amended and restated employment agreements for CEO R. Kirk Huntsman and CFO Bradford Amman, effective January 1, 2025, which include increased base salaries, incentive bonuses, and severance benefits. The agreements also contain restrictive covenants and provisions for severance benefits in the event of a Change in Control. Full details of the 2024 Omnibus Plan and the Amended Employment Agreements will be included in the company's upcoming Quarterly Report on Form 10-Q.